Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03411980 | Feb → Oct 2018 | endometriosis, leiomyoma | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03342859 | Nov 2017 → Dec 2018 | leiomyoma | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT03210246 | Jul 2017 → Jun 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03092999 | Mar → Jul 2017 | leiomyoma | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02975440 | Nov 2016 → Jan 2017 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02456129 | Jul → Sep 2015 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02262663 | Oct 2014 → Sep 2015 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01816815 | Nov 2011 → Oct 2012 | leiomyoma | Bayer | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT03573336 | Jul 2018 → Mar 2019 | endometriosis | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT02465814 | Jun 2015 → Oct 2016 | leiomyoma | Bayer | Completed | Met primary |
| Phase 2 | NCT02131662 | May 2014 → May 2016 | leiomyoma | Bayer | Completed | Met primary |
| Phase 36 trials · 2 met primary | ||||||
| Phase 3 | NCT03699176 | Oct 2018 → Dec 2019 | leiomyoma | Bayer | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03476928 | Mar 2018 → Jul 2021 | leiomyoma | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT03400956 | Jan 2018 → Mar 2019 | leiomyoma | Bayer | Terminated | Met primary |
| Phase 3 | NCT03400943 | Jan 2018 → Jun 2019 | leiomyoma | Bayer | Terminated | Met primary |
| Phase 3 | NCT03240523 | Jul 2017 → Jun 2020 | uterine benign neoplasm | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT03194646 | Jun 2017 → May 2019 | uterine benign neoplasm | Bayer | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-07-03 | Bayer | Bayer starts Phase III study program with Vilaprisan in the treatment of symptomatic uterine fibroids bayer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vilaprisan | “Vilaprisan (BAY 1002670) is a novel, highly potent selective progesterone receptor modulator that markedly reduces the growth of human leiomyoma tissue in a preclinical model...” PMID 27288475 ↗ Jun 201616“Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.” PMID 30527839 ↗ Dec 2018 |
| Known as | BAY1002670 | “Vilaprisan (BAY 1002670) is a novel, highly potent selective progesterone receptor modulator that markedly reduces the growth of human leiomyoma tissue in a preclinical model...” PMID 27288475 ↗ Jun 201615“The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal.” NCT02465814 ↗ “COC + Vilaprisan (BAY 1002670)” NCT03210246 ↗ “Drug: BAY1002670_Vilaprisan” NCT02975440 ↗ “Vilaprisan (BAY1002670)” NCT03400956 ↗ “Vilaprisan (BAY1002670)” NCT03400943 ↗ “Vilaprisan (BAY1002670)” NCT03240523 ↗ “Vilaprisan (BAY1002670)” NCT02456129 ↗ “Vilaprisan (BAY1002670)” NCT03194646 ↗ “Vilaprisan (BAY1002670)” NCT03092999 ↗ “Vilaprisan (BAY1002670)” NCT03476928 ↗ |
| Known as | VPR | “Does administration of vilaprisan (VPR) to healthy women for 12 weeks reduce menstrual bleeding?” PMID 27288475 ↗ Jun 20161“4 milligram (mg) Vilaprisan (VPR) tablet once daily orally” NCT02131662 ↗ |
| Modality | Other / unclassified | “a selective progesterone receptor modulator” PMID 29330782 ↗ Aug 2018 |
| Route | Oral | “oral administration” NCT01816815 ↗ |
| Target | PGR | “Progesterone receptor modulator” CHEMBL3989936 ↗ |